drugset / Trial / NCT03597412

Rosuvastatin/Ezetimibe Versus Rosuvastatin in ASCVD Patients With Type 2 DM

NCT03597412

Phase 4 Completed 236 enrolled Yuhan Corporation
RandomizedParallel-groupOpen-labelTreatment

Summary

This study will evaluate the efficacy and aafety of rosuvastatin/ezetimibe combination therapy vs. rosuvastatin monotherapy in atherosclerotic cardiovascular disease patients with type 2 diabetes mellitus

Timeline

Start
2018-10-17
Primary completion
2020-08-12
Completion
2020-08-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Ezetimibe Unknown 10 mg
Subject Rosuvastatin Small molecule 10 mg
Subject Rosuvastatin Small molecule 20 mg